Study closed due to poor accrual

The purpose of this study is to determine whether sutent (sunitinib)is effective in preventing tumor recurrence in patients with high risk bladder cancer who have previously had chemotherapy and cystectomy (bladder removal).

A 4 month supply of the drug is given to patients beginning 2-3 months after bladder removal. The patients are followed up to 2 years.

Inclusion Criteria:

• Histologic diagnosis of bladder carcinoma (>50% urothelial carcinoma)
• Prior treatment with at least one cycle of platin-based neoadjuvant chemotherapy
• Prior treatment with radical cystectomy revealing pT3NxM0 or pTanyN+M0
• ECOG performance status of 0-1 (Appendix 2).
• No evidence of metastases within 4 weeks of registration
• Adequate organ and marrow function obtained within 14 days of registration

Exclusion Criteria:

• Severe or uncontrolled acute or chronic medical or psychiatric condition
• Prior antiangiogenic therapy
• Prior pelvic radiation for bladder cancer

21.5 months - after that point no one was still in the trial